Hasty Briefsbeta

Bilingual

Baseline dual elevation of fractional exhaled nitric oxide and blood eosinophils is associated with clinical remission in severe eosinophilic asthma treated with biologics: a real-world prospective st

4 hours ago
  • #severe asthma
  • #clinical remission
  • #biologic therapy
  • Baseline dual elevation of FeNO and BEC is linked to clinical remission in severe eosinophilic asthma treated with biologics.
  • 69 patients with severe asthma were treated with benralizumab, mepolizumab, or dupilumab and classified into DHB-T2 or HNB-T2 groups based on biomarker levels.
  • 42 out of 69 patients (60.8%) achieved clinical remission at 12 months, with DHB-T2 status showing higher remission likelihood (OR 12.67, p=0.002).
  • DHB-T2 classification had 73.33% sensitivity and 62.45% specificity for identifying remission.
  • Isolated elevation of FeNO or BEC alone did not correlate with clinical remission.